RESUMO
OBJECTIVES: The Maraviroc Switch (MARCH) study week 48 data demonstrated that maraviroc, a chemokine receptor-5 (CCR5) inhibitor, was a safe and effective switch for the ritonavir-boosted protease inhibitor (PI/r) component of a two nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] plus PI/r-based antiretroviral regimen in patients with R5-tropic virus. Here we report the durability of this finding. METHODS: MARCH, an international, multicentre, randomized, 96-week open-label switch study, enrolled HIV-1-infected adults with R5-tropic virus who were stable (> 24 weeks) and virologically suppressed [plasma viral load (pVL) < 50 HIV-1 RNA copies/mL]. Participants were randomized to continue their current PI/r-based regimen (PI/r) or to switch to MVC plus two N(t)RTIs (MVC) (1:2 randomization). The primary endpoint was the difference in the proportion with pVL < 200 copies/mL at 96 weeks. The switch arm was defined as noninferior if the lower limit of the 95% confidence interval (CI) for the difference was < -12% in the intention-to-treat (ITT) population. Safety endpoints (the difference in the mean change from baseline or a comparison of proportions) were analysed as key secondary endpoints. RESULTS: Eighty-two (PI/r) and 156 (MVC) participants were randomized and included in the ITT analysis; 71 (87%) and 130 (83%) were in follow-up and on therapy at week 96. At week 96, 89.0% and 90.4% in the PI/r and MVC arms, respectively, had pVL < 50 copies/mL (95% CI -6.6, 10.2). Moreover, in those switching away from PI/r, there were significant reductions in mean total cholesterol (differences 0.31 mmol/L; P = 0.02) and triglycerides (difference 0.44 mmol/L; P < 0.001). Changes in CD4 T-cell count, renal function, and serious and nonserious adverse events were similar in the two arms. CONCLUSIONS: MVC as a switch for a PI/r is safe and effective at maintaining virological suppression while having significant lipid benefits over 96 weeks.
Assuntos
Terapia Antirretroviral de Alta Atividade/métodos , Antagonistas dos Receptores CCR5/administração & dosagem , Cicloexanos/administração & dosagem , Substituição de Medicamentos , Infecções por HIV/tratamento farmacológico , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Transcriptase Reversa/administração & dosagem , Triazóis/administração & dosagem , Adulto , Terapia Antirretroviral de Alta Atividade/efeitos adversos , Antagonistas dos Receptores CCR5/efeitos adversos , Cicloexanos/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Inibidores da Protease de HIV/efeitos adversos , HIV-1/isolamento & purificação , Humanos , Maraviroc , RNA Viral/sangue , Inibidores da Transcriptase Reversa/efeitos adversos , Resultado do Tratamento , Triazóis/efeitos adversos , Carga ViralRESUMO
BACKGROUND: The risk factors for coronavirus disease (COVID-19) among healthcare workers (HCWs) might have changed since the emergence of the highly immune evasive Omicron variant. AIM: To compare the risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among HCWs during the Delta- and Omicron-predominant periods. METHODS: Using data from repeated serosurveys among the staff of a medical research centre in Tokyo, two cohorts were established: Delta period cohort (N = 858) and Omicron period cohort (N = 652). The potential risk factors were assessed using a questionnaire. Acute/current or past SARS-CoV-2 infection was identified by polymerase chain reaction or anti-nucleocapsid antibody tests, respectively. Poisson regression was used to calculate the risk ratio (RR) of infection risk. FINDINGS: The risk of SARS-CoV-2 infection during the early Omicron-predominant period was 3.4-fold higher than during the Delta-predominant period. Neither working in a COVID-19-related department nor having a higher degree of occupational exposure to SARS-CoV-2 was associated with an increased infection risk during both periods. During the Omicron-predominant period, infection risk was higher among those who spent ≥30 min in closed spaces, crowded spaces, and close-contact settings without wearing mask (≥3 times versus never: RR: 6.62; 95% confidence interval: 3.01-14.58), whereas no such association was found during the Delta period. CONCLUSION: Occupational exposure to COVID-19-related work was not associated with the risk of SARS-CoV-2 infection in the Delta or Omicron period, whereas high-risk behaviours were associated with an increased infection risk during the Omicron period.
Assuntos
COVID-19 , Humanos , COVID-19/epidemiologia , Japão/epidemiologia , SARS-CoV-2 , Fatores de Risco , Pessoal de SaúdeRESUMO
Interpretation of Human Immunodeficiency Virus 1 (HIV-1) genotypic drug resistance is still a major challenge in the follow-up of antiviral therapy in infected patients. Because of the high degree of HIV-1 natural variation, complex interactions and stochastic behaviour of evolution, the role of resistance mutations is in many cases not well understood. Using Bayesian network learning of HIV-1 sequence data from diverse subtypes (A, B, C, F and G), we could determine the specific role of many resistance mutations against the protease inhibitors (PIs) nelfinavir (NFV), indinavir (IDV), and saquinavir (SQV). Such networks visualize relationships between treatment, selection of resistance mutations and presence of polymorphisms in a graphical way. The analysis identified 30N, 88S, and 90M for nelfinavir, 90M for saquinavir, and 82A/T and 46I/L for indinavir as most probable major resistance mutations. Moreover we found striking similarities for the role of many mutations against all of these drugs. For example, for all three inhibitors, we found that the novel mutation 89I was minor and associated with mutations at positions 90 and 71. Bayesian network learning provides an autonomous method to gain insight in the role of resistance mutations and the influence of HIV-1 natural variation. We successfully applied the method to three protease inhibitors. The analysis shows differences with current knowledge especially concerning resistance development in several non-B subtypes.
Assuntos
Teorema de Bayes , Farmacorresistência Viral/genética , Infecções por HIV/virologia , Inibidores da Protease de HIV/farmacologia , HIV-1/genética , Mutação , Infecções por HIV/tratamento farmacológico , Inibidores da Protease de HIV/uso terapêutico , HIV-1/efeitos dos fármacos , Humanos , Indinavir/farmacologia , Indinavir/uso terapêutico , Dados de Sequência Molecular , Nelfinavir/farmacologia , Nelfinavir/uso terapêutico , Saquinavir/farmacologia , Saquinavir/uso terapêuticoRESUMO
Specialized antigen-presenting cells (APC), known as dendritic cells (DC), play a pivotal role in initiating primary immune responses. Several vector systems, including adenoviral vectors, retroviral vectors, hemagglutinating virus of Japan-related vectors, and the electroporation, have been shown to transduce genes into mouse and human but not rat DC. However, there is no direct evidence to support the view that the currently used vector systems are able to transduce genes into mature DC. Inasmuch as most, if not all, gene transfer studies investigating DC or DC-related cell populations are performed employing heterogeneous-groups of cells, it is therefore important to determine the extent to which gene transduction occurs in bona fide DC. In this study, we provide evidence that none of these vector systems are able to transfer genes into mature rat DC, which are derived from bone marrow cells (BMC), driven by Flt3/Flk2 ligand and IL-6, and purified with CD161a. Nevertheless, the most efficient gene transduction was observed with developing DC progenitor cells during long-term culture of rat BMC. Successful gene transfer was achieved after 2-week culture with an HIV-based lentiviral vector system.
Assuntos
Células Apresentadoras de Antígenos/imunologia , Células Dendríticas/imunologia , Vetores Genéticos , Animais , Humanos , Proteínas de Membrana/genética , Protetores contra Radiação , Ratos , Transdução Genética/métodosRESUMO
The recently isolated paeonol (2-hydroxy-4-methoxyacetophenone), as one of the antimutagenic compounds from Discorea japonica, was used as a lead compound for detailed structure-activity relationship studies. Nine acetophenones (2-hydroxy-4-methoxy, 2-hydroxy-5-methoxy, 2-hydroxy-6-methoxy, 4-hydroxy-3-methoxy, o-methoxy, m-methoxy, p-methoxy, and 2,5-dimethoxyacetophenone and acetophenone) were investigated for their ability of suppression of furylfuramide-induced SOS response using Salmonella typhimurium TA1535/pSK1002 in the umu test, against the mutagen, 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (furylfuramide). The results showed that 2-hydroxy-6-methoxyacetophenone displayed the strongest activity (EC(50) = 0.6 micromol/mL), and a hydroxyl group at C-2 is necessary feature for acetophenone derivatives to show the suppressive effects of furylfuramide-induced SOS response.
Assuntos
Acetofenonas/farmacologia , Furilfuramida/farmacologia , Resposta SOS em Genética , Salmonella typhimurium/genéticaRESUMO
A bibenzyl compound that possesses antimutagenic activity was isolated from the storage stem of Dendrobium nobile. The isolated compound suppressed the expression of the umu gene following the induction of SOS response in Salmonella typhimurium TA1535/pSK1002 that have been treated with various mutagens. The suppressive compound was mainly localized in the n-hexane extract fraction of the processed D. nobile. This n-hexane fraction was further fractionated by silica gel column chromatography, which resulted in the purification and subsequent identification of the suppressive compound. EI-MS and (1)H and (13)C NMR spectroscopy were then used to delineate the structure of the compound that confers the observed antimutagenic activity. Comparison of the obtained spectrum with that found in the literature indicated that moscatilin is the secondary suppressive compound. When using 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (furylfuramide) as the mutagen, moscatilin suppressed 85% of the umu gene expression compared to the controls at <0.73 micromol/mL, with an ID(50) value of 0.41 micromol/mL. Additionally, moscatilin was tested for its ability to suppress the mutagenic activity of other well-known mutagens such as 4-nitroquinoline-1-oxide (4NQO), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), UV irradiation, 3-amino-1,4-dimethyl-5H-pyrido[4,3b]indole (Trp-P-1), benzo[a]pyrene (B[a]P), and aflatoxin B(1) (AFB(1)). With all of the aforementioned chemicals or treatments, moscatilin showed a dramatic reduction in their mutagenic potential. Interestingly, moscatilin almost completely suppressed (97%) the AFB(1)-induced SOS response at concentrations <0.73 micromol/mL, with an ID(50) of 0.08 micromol/mL. Finally, the antimutagenic activities of moscatilin against furylfuramide and Trp-P-1 were assayed by the Ames test using the S. typhimurium TA100 strain. The results those experiments indicated that moscatilin demonstrated a dramatic suppression of the mutagenicity of only Trp-P-1 but not furylfuramide.
Assuntos
Antimutagênicos/isolamento & purificação , Compostos de Benzil/isolamento & purificação , Plantas Medicinais/química , Antimutagênicos/química , Antimutagênicos/farmacologia , Compostos de Benzil/química , Compostos de Benzil/farmacologia , Hexanos , Testes de Mutagenicidade , Extratos Vegetais/química , Caules de Planta , Salmonella typhimurium/efeitos dos fármacosRESUMO
Three bacterial strains, which degraded azo dyes, were isolated from soil and sewage samples. The strains were identified as Bacillus sp. OY1-2, Xanthomonas sp. NR25-2 and Pseudomonas sp. PR41-1. The bacteria produced azo-dyes-degrading enzymes. That catalyzed the reduction of methyl red and produced dimethyl p-phenylenediamine and o-aminobenzoic acid. The enzymes could thus be applied to white discharge printing of azo-dyed fabric by owing to there.
RESUMO
We found that human urine suppressed SOS-responses induced by furylfuramide (AF-2), as detected by the umu test using Salmonella typhimurium TA1535/pSK1002. In the present report, we studied the time stability of the SOS-inhibition activity in urine. The diurnal and daily changes of SOS-inhibition in the urine were also observed. Results obtained were as follows; 1) SOS-inhibition activity of the urine remained stable more than one month after the urine was frozen. 2) Individual variation was observed in the SOS-inhibition activity of the urine. 3) Total SOS-inhibition activity of per a day showed relatively small variation during experimental days. 4) The SOS-inhibition activity of urine was higher early in the morning than in the daytime. The activity fell gradually with time in the daytime and showed the lowest value in the evening. Then, it rose again at night. Therefore, it is necessary to collect urine at specific times to avoid the differences caused by diurnal changes in SOS-inhibition activity.
Assuntos
Ritmo Circadiano , Testes de Mutagenicidade , Resposta SOS em Genética , Urina , Adulto , Criança , Pré-Escolar , Feminino , Furilfuramida/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Resposta SOS em Genética/efeitos dos fármacosRESUMO
We studied the usefulness of percutaneous instillation of antifungal agents for treatment of pulmonary aspergilloma. The subjects were six patients, four males and two females, with a mean age of 69 years (range, 45 to 90 years). In all cases, radiography revealed a fungus ball or thickened cavity wall in residual tuberculous cavities. The patients had clinical symptoms including hemoptysis, fever, cough and sputum, and most of them showed severe emaciation, anemia, hypoalbuminemia and hypoxia. Miconazole or fluconazole was instilled through an indwelling catheter inserted percutaneously into the cavity from the anterior chest wall or parascapular region under fluoroscopic observation. After treatment with a total dose of 610 to 2070 mg over a period of 6 to 18 weeks, clinical symptoms were diminished in all patients and radiographic findings were improved in five. Furthermore, Aspergillus fumigatus, which had been isolated from sputum samples of three patients, was eradicated. According to evaluation of the overall therapeutic effects, this therapy was considered to be effective in five patients, giving an efficacy rate of 83%. No recurrence has been detected in six patients during a mean follow-up of 13 months after treatment. Since percutaneous instillation involves less pain and stress than other kinds of
Assuntos
Antifúngicos/administração & dosagem , Aspergilose/tratamento farmacológico , Pneumopatias Fúngicas/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Feminino , Fluconazol/administração & dosagem , Humanos , Instilação de Medicamentos , Masculino , Miconazol/administração & dosagem , Pessoa de Meia-IdadeAssuntos
Citotoxicidade Imunológica , Antígeno H-Y/imunologia , Linfócitos T Citotóxicos/imunologia , Linfócitos T/imunologia , Animais , Medula Óssea/imunologia , Células da Medula Óssea , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Feminino , Antígeno H-Y/biossíntese , Imunização , Ativação Linfocitária , Teste de Cultura Mista de Linfócitos , Masculino , Ratos , Ratos Endogâmicos , Timidina/metabolismoAssuntos
Fármacos Anti-HIV/farmacologia , HIV/efeitos dos fármacos , Adulto , Fármacos Anti-HIV/uso terapêutico , Contagem de Linfócito CD4 , Resistência Microbiana a Medicamentos , Feminino , HIV/isolamento & purificação , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , Humanos , Incidência , Masculino , Tóquio/epidemiologia , Recusa do Paciente ao TratamentoAssuntos
Fármacos Anti-HIV/farmacologia , Infecções por HIV/virologia , HIV-1/efeitos dos fármacos , Fármacos Anti-HIV/uso terapêutico , Resistência Microbiana a Medicamentos/genética , Técnicas Genéticas , Genótipo , Infecções por HIV/tratamento farmacológico , HIV-1/classificação , HIV-1/genética , Humanos , MutaçãoAssuntos
Fármacos Anti-HIV/farmacologia , Infecções por HIV/virologia , HIV-1/genética , Mutação , Fármacos Anti-HIV/uso terapêutico , Resistência Microbiana a Medicamentos/genética , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , HIV-1/efeitos dos fármacos , Humanos , Japão/epidemiologia , Prevalência , RNA Viral/genéticaAssuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1/efeitos dos fármacos , Terapia Antirretroviral de Alta Atividade/métodos , Infecções por HIV/epidemiologia , Inibidores da Protease de HIV/uso terapêutico , Humanos , Japão/epidemiologia , Resultado do Tratamento , Carga Viral/tendênciasRESUMO
Microsporidian Encephalitozoon cuniculi has a unique organelle called a polar tube (PT), the extrusion of which is absolutely required to invade a host cell. We recently detected anti-E. cuniculi PT immunoglobulin (Ig) M antibodies in sera from many healthy individuals. The present one-dimensional (1-D) immunoblot analysis predominantly detected a band at 52 kDa in all of the examined human sera with anti-PT IgM. The use of mouse monoclonal antibody confirmed that the 52-kDa band detected in 1-D immunoblots was an antigen derived from the PT, which represents a glycoprotein nature. In addition, from changes in the immunoreactivity of the 52-kDa band before and after treatment with NaOH, we determined that the 24 human serum samples with anti-PT IgM activities could be roughly grouped into three types: (i) sera containing antibodies against only a saccharic determinant (n=3); (ii) sera containing antibodies against only a proteinic determinant (n=11); and (iii) sera showing dual recognition of saccharic and proteinic determinants (n=10). Further two-dimensional (2-D) immunoblot analysis followed by proteomic analysis confirmed that human sera with anti-PT IgM reacted with E. cuniculi polar tube protein 1 (PTP1). Such circulating IgM antibodies may be important in the first line of defence against E. cuniculi infection.
Assuntos
Anticorpos Antifúngicos/sangue , Encephalitozoon cuniculi/imunologia , Encefalitozoonose/imunologia , Proteínas Fúngicas/imunologia , Imunoglobulina M/sangue , Anticorpos Antifúngicos/imunologia , Concanavalina A/metabolismo , Encefalitozoonose/microbiologia , Ensaio de Imunoadsorção Enzimática , Humanos , Imunoglobulina M/imunologia , Microsporídios/imunologia , ProteômicaRESUMO
The biotransformation of oxazepam by Bifidobacterium bifidum was studied. The major metabolite was purified by chromatographic methods and found to be desmethyldiazepam using NMR, IR and other physicochemical data.
Assuntos
Bifidobacterium , Intestinos/microbiologia , Nordazepam/metabolismo , Oxazepam/metabolismo , Bifidobacterium/fisiologia , Biotransformação , Humanos , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Estrutura Molecular , Oxirredução , EspectrofotometriaRESUMO
Azo dyes are regarded as pollutants because they are not readily reduced under aerobic conditions. Bacillus sp. OY1-2 transforms azo dyes into colorless compounds, and this reduction is mediated by a reductase activity for the azo group in the presence of NADPH. A 1.2-kbp EcoRI fragment containing the gene that encodes azoreductase was cloned by screening the genomic library of Bacillus sp. OY1-2 with digoxigenin-labeled probe designed from the N-terminal amino acid sequence of the purified enzyme. An open reading frame encoding the azoreductase, consisting of 178 amino acids, was predicted from the nucleotide sequence. In addition, because only a Bacillus subtillis hypothetical protein was discovered in the public databases (with an amino acid identity of 52.8%), the gene encoding the azoreductase cloned in this study was predicted to be a member of a novel family of reductases. Southern blot analysis revealed that the azoreductase gene exists as a single copy gene on a chromosome. Escherichia coli-expressing recombinant azoreductase gave a ten times greater reducing activity toward azo dyes than the original Bacillus sp. OY1-2. In addition, the expressed azoreductase purified from the recombinant E. coli lysate by Red-Sepharose affinity chromatography showed a similar activity and specificity as the native enzyme. This is the first report describing the sequencing and characterization of a gene encoding the azo dye-reducing enzyme, azoreductase, from aerobic bacteria and its expression in E. coli.
Assuntos
Bacillus/genética , NADH NADPH Oxirredutases/genética , Microbiologia do Solo , Sequência de Aminoácidos , Bacillus/enzimologia , Bacillus/isolamento & purificação , Sequência de Bases , Clonagem Molecular , DNA Bacteriano , Escherichia coli/genética , Dados de Sequência Molecular , NADH NADPH Oxirredutases/química , NADH NADPH Oxirredutases/isolamento & purificação , Nitrorredutases , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/isolamento & purificação , Homologia de Sequência de AminoácidosRESUMO
Recent studies have found aberrant expression of class II antigens by bronchial epithelial cells (BECs), suggesting that these cells may also be involved in airway mucosal immunity. However, the regulation of class II antigen expression on BECs by cytokines and the functional capacity of such cells bearing class II molecules remain unknown. We investigated the effect of IFN-gamma on class II antigen expression by cultured rat BECs, as well as the ability of these cells to present intact protein antigens to specifically sensitized T cells. Although primary BECs did not express class II antigens, IFN-gamma readily induced their expression in a dose-dependent manner. More than 85% of the BECs treated with 1000 U/ml of IFN-gamma were positive for class II antigens. In addition, when IFN-treated BECs bearing class II molecules were pulsed with ovalbumin (OVA), they significantly stimulated the proliferation of OVA-sensitized T cells, whereas cells that were not treated with IFN-gamma but were pulsed with OVA did not do so. Our findings indicate that BECs bearing class II molecules are capable of presenting OVA to OVA-sensitized T cells. These results suggest that various pathological conditions causing the local production of IFN-gamma may increase class II antigen expression on BECs, which in turn may modulate the airway mucosal immune response by the presentation of antigens to T cells.